课题基金 / 基金详情

Targeting epigenetic regulation to disrupt glioma stem cell maintenance.

Targeting epigenetic regulation to disrupt glioma stem cell maintenance.
针对表观遗传调控来破坏神经胶质瘤干细胞的维持。
批准号:
8784783
负责人:
Tyler Eugene Miller
金额:
$4.77万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-07-15 至 2018-07-14

项目摘要

项目成果

Tyler Eugene Miller的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):胶质母细胞瘤(GBM)是最致命的人类癌症之一,常规治疗仅提供姑息治疗。在理解GBM遗传学和建模这些肿瘤方面已经取得了很大进展,新的靶向治疗正在测试中。不幸的是,这些进步并没有实质性地转化为改善患者的预后。已经开发了多种化学治疗剂和放射疗法来杀死癌细胞。然而,GBM对化疗和放疗的反应是适度的。显然,开发新的治疗策略或辅助策略以增强现有治疗的疗效的临床需求尚未得到满足。虽然没有单一的机制提供了目前GBM疗法的失败,包括我们自己的几个实验室已经表明,GBM肿瘤含有干细胞样细胞,称为癌症干细胞(CSC)。癌症干细胞假说假定肿瘤细胞以层级组织,CSC位于顶端。CSC对细胞毒性疗法具有抗性(Bao et al. Nature 2006)并促进肿瘤血管生成(Bao et al. Cancer Research 2006),支持直接的临床相关性。我们的小组和其他人已经表明,CSC位于血管周围和缺氧小生境中的特定功能小生境中(Li et al. Cancer Cell 2009; Lathia et al. Cell Stem Cell 2010),靶向这些小生境可能会破坏肿瘤维持和治疗抗性。值得注意的是,我们的小组已经发现,微环境通过表观遗传调节剂的诱导将分化的肿瘤细胞直接重编程为CSC(Heddavidel等人,Cell Death Diff. 2012年)。虽然靶向癌症中的表观遗传调节的几种疗法已经开发了很长时间,并且在临床上(例如HDAC抑制剂和阿扎胞苷),但是基于表观遗传调节在许多疾病(特别是癌症)中起核心作用的大量累积证据,对靶向这类分子重新产生了兴趣。主要的制药公司和研究机构已经开发了大型项目,试图以这些分子为目标。随着表观遗传药物开发的复苏和表观遗传调控控制细胞状态的证据,我开始确定新的表观遗传靶点,这些靶点是GBM中CSC状态的关键调控因子。我进行了一项靶向RNAi筛选,重点是组蛋白去甲基化酶,这是一类关键的表观遗传修饰基因。由于表观遗传修饰以及因此细胞状态至少部分地由微环境决定,因此我利用最先进的RNAi筛选技术在功能性原位微环境存在下进行体内筛选。在筛选的31个组蛋白去甲基化酶基因中,确定了三个候选靶点,临床生存和基因表达数据支持它们作为治疗靶点的潜力。如何CSC和正常的神经祖细胞生物学是通过靶向这些命中的影响,现在将进行评估。
英文摘要
DESCRIPTION (provided by applicant): Glioblastoma (GBM) ranks among the most lethal of human cancers with conventional therapy offering only palliation. Great strides have been made in understanding GBM genetics and modeling these tumors, and new targeted therapies are being tested. Unfortunately, these advances have not substantially translated into improved patient outcomes. Multiple chemotherapeutic agents and radiation therapy have been developed to kill cancer cells. However, the response to chemotherapy and radiation in GBM is modest. There is clearly an unmet clinical need to develop either a novel treatment strategy or an adjuvant strategy to enhance efficacy of existing treatments. While no single mechanism provides for the failure of current GBM therapies, several laboratories including our own have shown that GBM tumors contain stem cell-like cells termed cancer stem cells (CSCs). The cancer stem cell hypothesis posits that tumor cells are organized in a hierarchy with CSCs at the apex. CSCs are resistant to cytotoxic therapies (Bao et al. Nature 2006) and promote tumor angiogenesis (Bao et al. Cancer Research 2006) supporting a direct clinical relevance. Our group and others have shown that CSCs reside in specific functional niches in perivascular and hypoxic niches (Li et al. Cancer Cell 2009; Lathia et al. Cell Stem Cell 2010), and targeting these niches may disrupt tumor maintenance and therapeutic resistance. Notably, our group has found that the microenvironment directly reprograms differentiated tumor cells into CSCs through the induction of epigenetic regulators (Heddleston et al. Cell Death Diff. 2012). While several therapies targeting epigenetic regulation in cancer have long been developed and in the clinic (e.g. HDAC inhibitors and Azacitidine) there has been a renewed interest in targeting this class of molecules based on the large amount of accumulating evidence that epigenetic regulation plays a central role in many diseases, particularly cancer. Major pharmaceutical companies and research agencies have developed large programs to try to target these moecules. With this resurgence of epigenetic drug development and evidence that epigenetic regulation controls cell state, I set out to identify novel epigenetic targets that are critical regulators of the CSC state in GBM. I conducted a targeted RNAi screen that focused on histone demethylases, a key class of epigenetic modifying genes. As epigenetic modifications, and therefore cell state are at least partially determined by the microenvironment, I utilized state-of-the-art RNAi screening technology to conduct the screen in vivo in the presence of a functional orthotopic microenvironment. Out of 31 histone demethylase genes screened, three candidate targets were identified, and clinical survival and gene expression data supports their potential as therapeutic targets. How CSC and normal neural progenitor biology is affect by targeting these hits will now be evaluated.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting myeloid cells to increase efficacy of immunotherapy against brain tumors.
  • 批准号:
    10571040
  • 项目类别:
  • 资助金额:
    $21.15万
  • 财政年份:
    2023
  • 负责人:
    Tyler Eugene Miller
  • 依托单位:
Targeting epigenetic regulation to disrupt glioma stem cell maintenance.
  • 批准号:
    9703058
  • 项目类别:
  • 资助金额:
    $4.25万
  • 财政年份:
    2014
  • 负责人:
    Tyler Eugene Miller
  • 依托单位:
海外基金